Home - Melanoma Research Alliance

Challenge Accepted

This was a year like no other.

COVID-19 presented new challenges that required new ways of thinking. At MRA, confronting challenges is part of our DNA. We never stop challenging ourselves, no matter the odds or obstacles, in pursuit of conquering melanoma and saving lives.

Read our 2020 - 2021 Annual Report where you can find examples of our work, latest newest grantees, audited financials, & more.

Read the Annual Report

New Melanoma Research Funding

MRA is pleased to announce a Request for Proposals (RFP) for pre-clinical, translational, and early clinical research with the potential to produce unusually high impact, near-term advancements in melanoma prevention, detection, diagnosis, staging, and treatment.

This award cycle is anticipated to support at least $11.3 million in new funding.

Learn More

Craig Finds Meaning in His Melanoma Diagnosis in the COVID-19 Era

“I believe there is a reason that I’m going through this. If I can help prevent someone else’s melanoma, or make their journey easier, or help advance research – that’d be worth it,” says Craig. “I feel honored to be part of the melanoma community. It’s a powerful community – and I feel obligated to do something in support of it.”

Promising Uveal Melanoma Research Advances

Uveal melanoma, often called ocular melanoma or just eye melanoma, is a rare melanoma subtype that affects about 2,500 people each year in the United States. As is true with other rare subtypes, we know far less about what causes uveal melanoma, how it progresses, and how it can be effectively treated. Research focused on rare subtypes is urgently needed and this is why the flurry of recent advances focused on uveal melanoma are so exciting.